XenoPort promotes Angotti and Bates; slims down workforce
This article was originally published in Scrip
Executive Summary
XenoPort, a biopharmaceutical company focused on neurological disorders, has promoted Vincent Angotti to the role of executive vice-president and COO and Gregory Bates to senior vice-president of regulatory affairs and quality. Mr Angotti was previously senior vice-president and chief commercialisation officer, while Mr Bates was vice-president of regulatory affairs.